Group 1: Share Buyback Announcement - The company approved a share buyback plan at the shareholder meetings held on December 24, 2024, and May 29, 2025, with a total amount not less than RMB 60 million and not exceeding RMB 100 million, at a price not exceeding RMB 45.00 per share [2][3] - As of December 23, 2025, the company completed the buyback of 16,193,259 A-shares, accounting for 1.79% of the total share capital, with a total expenditure of RMB 600,217,787.75 [3][4] - The repurchased shares will be fully canceled, leading to a reduction in registered capital, and the company will submit the cancellation application to the relevant authorities [3][6] Group 2: Compliance and Implementation - The buyback process complied with relevant regulations, and the total funds used, repurchase price, and number of shares repurchased were consistent with the approved plan [5][6] - The company did not engage in stock trading during sensitive periods, ensuring compliance with trading regulations [10][11] Group 3: New Drug Application - The company’s subsidiary received a notice from the National Medical Products Administration regarding the acceptance of the registration application for "Lai Kang Qi Ta Monoclonal Antibody Injection" [16][17] - This drug is a first-in-class IL-17A/F dual-target inhibitor for treating moderate to severe plaque psoriasis, with promising clinical trial results showing superior efficacy compared to the control group [18][20] - The total R&D investment for this drug has reached approximately RMB 20.4 million, and there are currently no approved products for the same indication in the domestic market [20]
丽珠医药集团股份有限公司 关于A股股份回购结果暨股份 变动公告